| Ovarian cancer,the fifth leading cause of death in women,has a mortality rate among the highest of all gynecological malignancies,affecting anywhere from 2.4% to 5.6% of the female population.Due to the fact that most individuals are diagnosed in the advanced stages of the disease,combining cytoreductive surgery with post-operative chemotherapy is now a prominent treatment choice.Chemotherapy is highly effective in the treatment of ovarian cancer,particularly in epithelial ovarian cancer,even in cases where the cancer has metastasised extensively.The NCCN(National Comprehensive Cancer Network)has prescribed that platinum-containing combinations be the first line of treatment for epithelial ovarian cancer patients when it comes to chemotherapy.Patients with epithelial ovarian cancer have seen a remarkable rise in their 5-year survival rate,with 45%,due to the combination of paclitaxel and platinum.platinum-based drugs were developed in the 1960s and have been used in the treatment of a wide range of clinical malignancies since the introduction of cisplatin(DDP)as the first generation of platinum-based antitumour drugs in the USA in 1978.Currently,platinum-based drugs have been successfully developed into the third generation,with the first generation represented by cisplatin,the second generation including carboplatin(CBP)and nedaplatin(NDP),and the third generation represented by loplatin(LBP)and oxaliplatin(OXA).In spite of the fact that platinum-based combination chemotherapy treatments are successful in the initial stages of treating ovarian cancer,they do not notably extend the median survival time of ovarian cancer patients.The majority of patients suffering from advanced ovarian cancer will experience either metastases or recurrence after using platinum-based treatments,or they will become resistant to these therapies,which often results in treatment failure and a reduced long-term survival rate.In the management of cancer patients,the primary obstacle to successful treatment is the tumor’s ability to resist,so platinum resistance may present an impediment in the clinical treatment of ovarian cancer.It is essential to find ways to overcome the effects of chemoresistance when treating ovarian cancer.Since the late 1980s,YBX1 has been subject to much research due to its multifunctional nature as a member of the cold shock protein superfamily.It is an essential factor in tumour development,impacting cell proliferation and differentiation,stress response,and drug resistance.Studies in the field of oncology have shown that YBX1,as a transcriptional and translational regulator of oncogenes,can regulate the growth,proliferation,invasion and apoptosis of tumour cells,and participate in and mediate the process of resistance to chemotherapy,endocrine therapy and immunotherapy.This element,expressed in a multitude of cancerous cells,has a deep influence on their biology,thus significantly contributing to a variety of cancers,such as renal cell carcinoma,breast cancer,gastric cancer,and prostate cancer.Investigations conducted in the beginning have proposed that certain inhibitors of the YBX1 signaling pathway,combined with the suppression of YBX1 expression or the suppression of BCRP expression,could potentially augment the efficacy of chemotherapy and enhance the treatment of cancer.However,there is a paucity of data on YBX1 in ovarian cancer.We initially ascertained the elevated expression of YBX1 in ovarian cancer through clinical data analysis,Our research revealed that the upregulation of YBX1 could reduce the apoptotic effect of platinum on ovarian cancer cells and bolster their resistance to platinum-based therapeutic agents,after modifying its expression level with lentiviral-packaged shRNA knockdown or overexpression techniques. |
PDF Full Text Request